{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:30:00Z","timestamp":1773833400753,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,17]]},"DOI":"10.7759\/cureus.17240","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T08:44:56Z","timestamp":1629189896000},"source":"Crossref","is-referenced-by-count":5,"title":["Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management"],"prefix":"10.7759","author":[{"given":"Deepak","family":"Verma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amena","family":"Firoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer Krishna Prasad","family":"Garlapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanmay","family":"Sai Charaan Reddy Sathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Haris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibek","family":"Dhungana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barun","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunjan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibek","family":"Kc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Palak","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2019.04.001","article-title":"Cardiorenal syndrome: pathophysiology","volume":"37","author":"Kumar U","year":"2019","unstructured":"Kumar U, Wettersten N, Garimella PS. Cardiorenal syndrome: pathophysiology. Cardiol Clin. 2019, 37:251-65. 10.1016\/j.ccl.2019.04.001","journal-title":"Cardiol Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami J","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JE, et al.. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019, 139:e840-78. 10.1161\/CIR.0000000000000664","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2018.08.008","article-title":"Diuretics in the management of cardiorenal syndrome","volume":"25","author":"Chitturi C","year":"2018","unstructured":"Chitturi C, Novak JE. Diuretics in the management of cardiorenal syndrome. Adv Chronic Kidney Dis. 2018, 25:425-33. 10.1053\/j.ackd.2018.08.008","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2019.04.002","article-title":"Treatment of cardiorenal syndrome","volume":"37","author":"Rubinstein J","year":"2019","unstructured":"Rubinstein J, Sanford D. Treatment of cardiorenal syndrome. Cardiol Clin. 2019, 37:267-73. 10.1016\/j.ccl.2019.04.002","journal-title":"Cardiol Clin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2174\/1574886313666180226103408","article-title":"Risks associated with SGLT2 inhibitors: an overview","volume":"13","author":"Singh M","year":"2018","unstructured":"Singh M, Kumar A. Risks associated with SGLT2 inhibitors: an overview. Curr Drug Saf. 2018, 13:84-91. 10.2174\/1574886313666180226103408","journal-title":"Curr Drug Saf"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey CJ","year":"2019","unstructured":"Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab. 2019, 21:1291-8. 10.1111\/dom.13670","journal-title":"Diabetes Obes Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1753944720939383","article-title":"Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation","volume":"14","author":"Sano M","year":"2020","unstructured":"Sano M. Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation. Ther Adv Cardiovasc Dis. 2020, 14:1753944720939383. 10.1177\/1753944720939383","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.14740\/cr553w","article-title":"Cardiorenal syndrome: role of arginine vasopressin and vaptans in heart failure","volume":"8","author":"Vinod P","year":"2017","unstructured":"Vinod P, Krishnappa V, Chauvin AM, Khare A, Raina R. Cardiorenal syndrome: role of arginine vasopressin and vaptans in heart failure. Cardiol Res. 2017, 8:87-95. 10.14740\/cr553w","journal-title":"Cardiol Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2018.12.023","article-title":"Cardiorenal status using amino-terminal pro-brain natriuretic peptide and cystatin C on cardiac resynchronization therapy outcomes: from the BIOCRT Study","volume":"16","author":"Truong QA","year":"2019","unstructured":"Truong QA, Szymonifka J, Januzzi JL, Contractor JH, Dea\u00f1o RC, Chatterjee NA, Singh JP. Cardiorenal status using amino-terminal pro-brain natriuretic peptide and cystatin C on cardiac resynchronization therapy outcomes: from the BIOCRT Study. Heart Rhythm. 2019, 16:928-35. 10.1016\/j.hrthm.2018.12.023","journal-title":"Heart Rhythm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.14740\/cr955","article-title":"An update on the pathophysiology and treatment of cardiorenal syndrome","volume":"11","author":"Raina R","year":"2020","unstructured":"Raina R, Nair N, Chakraborty R, Nemer L, Dasgupta R, Varian K. An update on the pathophysiology and treatment of cardiorenal syndrome. Cardiol Res. 2020, 11:76-88. 10.14740\/cr955","journal-title":"Cardiol Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.03.051","article-title":"In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"46","author":"Abraham WT","year":"2005","unstructured":"Abraham WT, Adams KF, Fonarow GC, et al.. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005, 46:57-64. 10.1016\/j.jacc.2005.03.051","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2013.09.001","article-title":"Quantifying the effect of cardiorenal syndrome on mortality after left ventricular assist device implant","volume":"32","author":"Kirklin JK","year":"2013","unstructured":"Kirklin JK, Naftel DC, Kormos RL, et al.. Quantifying the effect of cardiorenal syndrome on mortality after left ventricular assist device implant. J Heart Lung Transplant. 2013, 32:1205-13. 10.1016\/j.healun.2013.09.001","journal-title":"J Heart Lung Transplant"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker GM","year":"2011","unstructured":"Felker GM, Lee KL, Bull DA, et al.. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011, 364:797-805. 10.1056\/NEJMoa1005419","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy CW","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al.. 2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013, 128:1810-52. 10.1161\/CIR.0b013e31829e8807","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.933275","article-title":"Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival","volume":"122","author":"Testani JM","year":"2010","unstructured":"Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010, 122:265-72. 10.1161\/CIRCULATIONAHA.109.933275","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-012-0129-1","article-title":"Cardiorenal syndrome and the role of ultrafiltration in heart failure","volume":"10","author":"Prosek J","year":"2013","unstructured":"Prosek J, Agarwal A, Parikh SV. Cardiorenal syndrome and the role of ultrafiltration in heart failure. Curr Heart Fail Rep. 2013, 10:81-8. 10.1007\/s11897-012-0129-1","journal-title":"Curr Heart Fail Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02910313","article-title":"Cardiorenal syndrome: ultrafiltration therapy for heart failure--trials and tribulations","volume":"8","author":"Kazory A","year":"2013","unstructured":"Kazory A. Cardiorenal syndrome: ultrafiltration therapy for heart failure--trials and tribulations. Clin J Am Soc Nephrol. 2013, 8:1816-28. 10.2215\/CJN.02910313","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2019-0422","article-title":"Heart failure and acute renal dysfunction in the cardiorenal syndrome","volume":"20","author":"Chahal RS","year":"2020","unstructured":"Chahal RS, Chukwu CA, Kalra PR, Kalra PA. Heart failure and acute renal dysfunction in the cardiorenal syndrome. Clin Med (Lond). 2020, 20:146-50. 10.7861\/clinmed.2019-0422","journal-title":"Clin Med (Lond)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000116764.53225.A9","article-title":"Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study","volume":"109","author":"McAlister FA","year":"2004","unstructured":"McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004, 109:1004-9. 10.1161\/01.CIR.0000116764.53225.A9","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators","volume":"341","author":"Pitt B","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators. N Engl J Med. 1999, 341:709-17. 10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in Type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in Type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0903-4","article-title":"Class effects of SGLT2 inhibitors on cardiorenal outcomes","volume":"18","author":"Kluger AY","year":"2019","unstructured":"Kluger AY, Tecson KM, Lee AY, et al.. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019, 18:99. 10.1186\/s12933-019-0903-4","journal-title":"Cardiovasc Diabetol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2020.16.2.113","article-title":"Cardiorenal syndrome in Type 2 diabetes mellitus - rational use of sodium-glucose cotransporter-2 Inhibitors","volume":"16","author":"Kalra S","year":"2020","unstructured":"Kalra S, Aydin H, Sahay M, et al.. Cardiorenal syndrome in Type 2 diabetes mellitus - rational use of sodium-glucose cotransporter-2 Inhibitors. Eur Endocrinol. 2020, 16:113-21. 10.17925\/EE.2020.16.2.113","journal-title":"Eur Endocrinol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.06.040","article-title":"Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review","volume":"72","author":"Zelniker TA","year":"2018","unstructured":"Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2018, 72:1845-55. 10.1016\/j.jacc.2018.06.040","journal-title":"J Am Coll Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00275.2019","article-title":"Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective","volume":"318","author":"Silva Dos Santos D","year":"2020","unstructured":"Silva Dos Santos D, Polidoro JZ, Borges-J\u00fanior FA, Girardi AC. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective. Am J Physiol Cell Physiol. 2020, 318:C328-36. 10.1152\/ajpcell.00275.2019","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.10.1639","article-title":"V2 receptor antagonism with tolvaptan in heart failure","volume":"16","author":"Costello-Boerrigter LC","year":"2007","unstructured":"Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. V2 receptor antagonism with tolvaptan in heart failure. Expert Opin Investig Drugs. 2007, 16:1639-47. 10.1517\/13543784.16.10.1639","journal-title":"Expert Opin Investig Drugs"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1159\/000441283","article-title":"Current and potential therapeutic strategies for hemodynamic cardiorenal syndrome","volume":"6","author":"Obi Y","year":"2016","unstructured":"Obi Y, Kim T, Kovesdy CP, Amin AN, Kalantar-Zadeh K. Current and potential therapeutic strategies for hemodynamic cardiorenal syndrome. Cardiorenal Med. 2016, 6:83-98. 10.1159\/000441283","journal-title":"Cardiorenal Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam MA","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr, et al.. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007, 297:1319-31. 10.1001\/jama.297.12.1319","journal-title":"JAMA"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3355\/ce.2008.010","article-title":"Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome","volume":"3","author":"Aghel A","year":"2008","unstructured":"Aghel A, Wilson Tang WH. Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome. Core Evid. 2008, 3:31-43. 10.3355\/ce.2008.010","journal-title":"Core Evid"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-018-0397-5","article-title":"Decompensated Heart Failure and Renal Failure: What Is the Current Evidence?","volume":"15","author":"Bielecka-Dabrowa A","year":"2018","unstructured":"Bielecka-Dabrowa A, Godoy B, Schefold JC, Koziolek M, Banach M, von Haehling S. Decompensated Heart Failure and Renal Failure: What Is the Current Evidence?. Curr Heart Fail Rep. 2018, 15:224-38. 10.1007\/s11897-018-0397-5","journal-title":"Curr Heart Fail Rep"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/168461","article-title":"Cardiac resynchronization therapy in the cardiorenal syndrome","volume":"2011","author":"Davis MK","year":"2011","unstructured":"Davis MK, Virani SA. Cardiac resynchronization therapy in the cardiorenal syndrome. Int J Nephrol. 2011, 2011:168461. 10.4061\/2011\/168461","journal-title":"Int J Nephrol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/pace.12685","article-title":"Renal response in patients with chronic kidney disease predicts outcome following cardiac resynchronization therapy","volume":"38","author":"Singal G","year":"2015","unstructured":"Singal G, Upadhyay GA, Borgquist R, et al.. Renal response in patients with chronic kidney disease predicts outcome following cardiac resynchronization therapy. Pacing Clin Electrophysiol. 2015, 38:1192-200. 10.1111\/pace.12685","journal-title":"Pacing Clin Electrophysiol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000144271.59333.a7","article-title":"Sustained sympathoinhibitory effects of cardiac resynchronization therapy in severe heart failure","volume":"44","author":"Grassi G","year":"2004","unstructured":"Grassi G, Vincenti A, Brambilla R, et al.. Sustained sympathoinhibitory effects of cardiac resynchronization therapy in severe heart failure. Hypertension. 2004, 44:727-31. 10.1161\/01.HYP.0000144271.59333.a7","journal-title":"Hypertension"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00750113","article-title":"Cardiac resynchronization therapy in CKD: a systematic review","volume":"8","author":"Garg N","year":"2013","unstructured":"Garg N, Thomas G, Jackson G, Rickard J, Nally JV Jr, Tang WH, Navaneethan SD. Cardiac resynchronization therapy in CKD: a systematic review. Clin J Am Soc Nephrol. 2013, 8:1293-303. 10.2215\/CJN.00750113","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq403","article-title":"Renal function and mortality following cardiac resynchronization therapy","volume":"32","author":"Lin G","year":"2011","unstructured":"Lin G, Gersh BJ, Greene EL, Redfield MM, Hayes DL, Brady PA. Renal function and mortality following cardiac resynchronization therapy. Eur Heart J. 2011, 32:184-90. 10.1093\/eurheartj\/ehq403","journal-title":"Eur Heart J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/66614-emerging-treatments-of-cardiorenal-syndrome-an-update-on-pathophysiology-and-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:00Z","timestamp":1707507240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/66614-emerging-treatments-of-cardiorenal-syndrome-an-update-on-pathophysiology-and-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.17240","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,17]]}}}